Gulfstream Daily Brief
A concise weekday briefing for regulatory affairs professionals in pharma and biotech, focused on the United States, Europe, and ICH.
Free weekday email
The short brief arrives each weekday morning with direct links to the official publications.
Today’s brief centers on evidence expectations and regulatory adaptability. FDA has rewritten its hepatic impairment study framework, while MHRA has moved from questions about pivotal data to market action on avacopan and outlined powers that could alter how UK device rules evolve.
Read today's briefDaily Brief archive
Each weekday edition is preserved here with direct links to its official sources.
1 edition
FDA updates hepatic impairment study expectations as MHRA acts on pivotal data concerns and signals possible UK device reforms.
Read edition